OpportunityAnalyzer: Diabetic Foot Ulcers – Opportunity Analysis and Forecast to 2025

Summary

Diabetic Foot Ulcer (DFU) and Diabetic Foot Infection (DFI) market is set to triple in value from $292.1 Million in 2015 to $873.4 Million by 2025, representing a compound annual growth rate of 11.6%, this relatively strong growth, which will occur across the seven major markets of the US, France, Germany, Italy, Spain, the UK, and Japan, will be driven by a number of factors. These include the rising number of patients suffering from DFU, the introduction of new drug Granexin, and an increased emphasis on the cost-effectiveness of advanced DFU treatments in preventing serious complications.

The US is the largest market for DFU, DFI therapies, contributing approximately 62% of total sales in the base year and it is estimated that a novel wound healing therapy (FirstString’s Granexin) to be the strongest driver of growth in the DFU market in the 7MM, reaching sales of $570.3M in 2025.

According to Jesus Cuaron, Senior Analyst, the DFU market is expected to experience moderate changes over the next decade, with prospects for treatments entering the space looking bleak. Currently, FirstString’s Phase III candidate Granexin is the most promising drug in the DFU space. It statistically increases the rate of 100% wound closure compared to DFU standard of care.

Indeed, a number of wound-healing pipeline agents have recently failed clinical trials, primarily due to the lack of improved efficacy compared to current DFU standard-of-care practices, including products such as CytoTools’ DermaPro, an intralesional formulation of diperoxochloric acid, and Olympus Biotech’s topical trafermin spray. Overall, the development of novel DFU products has been very risky.

The report “OpportunityAnalyzer: Diabetic Foot Ulcers – Opportunity Analysis and Forecast to 2025” provides a detail overview of DFUs and DFIs, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, treatment guidelines and analysis of the current and future market competition in the global DFU and DFI therapeutics market.

Companies mentioned in this report: Advanced BioHealing, Advanced Tissue Sciences, CoDa Therapeutics, FirstString Research, Genentech, GlaxoSmithKline (GSK), Johnson & Johnson (J&J), Healthpoint Biotherapeutics Kaken Pharmaceutical, Lakewood-Amedex, MiMedx, Relief Therapeutics, Scios, Shire, Shire Regenerative Medicine, Smith & Nephew, Stryker Biotech, Olympus, Olympus Biotech, Organogenesis, Osiris Therapeutics.

Scope

– Overview of DFUs and DFIs, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.

– Annualized DFU therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2015 and forecast for ten years to 2025.

– Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the DFU and DFI therapeutics market.

– Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.

– Analysis of the current and future market competition in the global DFU and DFI therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to –

– Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.

– Develop business strategies by understanding the trends shaping and driving the global DFU and DFI therapeutics market.

– Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global DFU therapeutics market in future.

– Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.

– Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

– Track drug sales in the global DFU and DFI therapeutics market from 2015-2025.

– Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.